Nishi Shah, MD

Articles by Nishi Shah, MD

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

ByMendel Goldfinger, MD,Nishi Shah, MD,Dennis L. Cooper, MD

March 22nd 2023

Although the first FDA approval for CAR T-cell therapy in multiple myeloma was 2 years ago, unfortunately, the treatment remains out of reach for too many patients.

Latest Updated Articles

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability
Published: March 22nd 2023 | Updated:

Nishi Shah, MD

Articles by Nishi Shah, MD

CAR T-Cell Therapy for Multiple Myeloma: Eliminating Disparities Through Accountability

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma